stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective Database

You may be eligible if

• Patients ≥18 years
• Histological diagnosis of breast cancer
• Oligometastatic or oligoprogressive metastatic breast cancer
• SBRT delivered to a minimum dose of 50Gy EQD2 (αβ 10 Gy),in a maximum of 12 fractions as per Oligocare definition
• Ability to provide written informed consent